Vaxxinity Inc Class A VAXX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vaxxinity Inc is a biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based active immunotherapy medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer’s, Parkinson’s, migraine, and hypercholesterolemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 53
- Website
- https://www.vaxxinity.com
Comparables
Valuation
|
Metric
|
VAXX
|
XERS
|
AVIR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.00 | — | 0.61 |
Price/Sales | — | 2.32 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
VAXX
XERS
AVIR
Financial Strength
|
Metric
|
VAXX
|
XERS
|
AVIR
|
|---|---|---|---|
Quick Ratio | 1.75 | 1.59 | 18.87 |
Current Ratio | 1.89 | 2.26 | 19.02 |
Interest Coverage | −83.80 | −1.24 | — |
Quick Ratio
VAXX
XERS
AVIR
Profitability
|
Metric
|
VAXX
|
XERS
|
AVIR
|
|---|---|---|---|
Return on Assets (Normalized) | −67.69% | −15.27% | −23.62% |
Return on Equity (Normalized) | −136.96% | — | −25.11% |
Return on Invested Capital (Normalized) | −101.16% | −13.23% | −29.21% |
Return on Assets
VAXX
XERS
AVIR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Yprlwrmtz | Ngr | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tpgtkkq | Xrmydw | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qnyvrbqf | Kswygjg | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bcjhtnk | Jsdzps | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Xyqrggwzy | Yyzb | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Ffgpmgjw | Pgll | $29.2 Bil | |||
| Moderna Inc
MRNA
| Zqwllndk | Mfr | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Shmlhwqgk | Hflz | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Fxmmkxlph | Mfdbd | $13.2 Bil | |||
| Incyte Corp
INCY
| Lrsmtws | Yfnhlh | $13.0 Bil |
United States